Sanofi (SNY)
Pre-market:
- GlobeNewswire
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativ
- Insider Monkey
25 Most Valuable European Companies Heading into 2024
In this article, we will be taking a look at the 25 most valuable European companies heading into 2024. To skip our detailed analysis, you can go directly to see the 5 most valuable European companies heading into 2024. Europe is considered to be the most advanced region in the world, especially in terms of standard […]
- Zacks
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
